Tempest Therapeutics Reports Q3 2026 Results, $0.9 Million Cash Balance

Tempest Therapeutics reported a third-quarter 2026 net loss of $3.6 million, or $0.21 per share, and ended September with $0.9 million in cash. The company said its cash is expected to fund operating expenses for less than 12 months from the date its financial statements were available to be issued…